Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical OutcomesJournal of clinical oncology, 2019-02, Vol.37 (4), p.278-285 [Peer Reviewed Journal]2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.18.01585 ;PMID: 30550363Full text available |
|
2 |
Material Type: Article
|
miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cellsPloS one, 2013-03, Vol.8 (3), p.e60317-e60317 [Peer Reviewed Journal]COPYRIGHT 2013 Public Library of Science ;2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Chen et al 2013 Chen et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0060317 ;PMID: 23555954Full text available |
|
3 |
Material Type: Article
|
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung CancerThe New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2027071 ;PMID: 32955177Full text available |
|
4 |
Material Type: Article
|
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung CancerThe New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1910231 ;PMID: 31562796Full text available |
|
5 |
Material Type: Article
|
Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung CancerThe New England journal of medicine, 2022-01, Vol.386 (3), p.241-251 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2112431 ;PMID: 34534430Full text available |
|
6 |
Material Type: Article
|
Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancerPloS one, 2012-04, Vol.7 (4), p.e35065-e35065 [Peer Reviewed Journal]COPYRIGHT 2012 Public Library of Science ;COPYRIGHT 2012 Public Library of Science ;2012 Lv et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Lv et al. 2012 ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0035065 ;PMID: 22493729Full text available |
|
7 |
Material Type: Article
|
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyThe lancet oncology, 2018-01, Vol.19 (1), p.139-148 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Jan 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30729-5 ;PMID: 29174310Full text available |
|
8 |
Material Type: Article
|
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerThe New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1709937 ;PMID: 28885881Full text available |
|
9 |
Material Type: Article
|
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancerBritish journal of cancer, 2019-09, Vol.121 (6), p.490-496 [Peer Reviewed Journal]Copyright Nature Publishing Group Sep 2019 ;The Author(s), under exclusive licence to Cancer Research UK 2019 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-019-0541-3 ;PMID: 31388183Full text available |
|
10 |
Material Type: Article
|
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLCThe New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1917346 ;PMID: 32997907Full text available |
|
11 |
Material Type: Article
|
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerThe New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1801005 ;PMID: 29658856Full text available |
|
12 |
Material Type: Article
|
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trialBMC cancer, 2020-08, Vol.20 (1), p.764-10, Article 764 [Peer Reviewed Journal]COPYRIGHT 2020 BioMed Central Ltd. ;COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-020-07263-9 ;PMID: 32795284Full text available |
|
13 |
Material Type: Article
|
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expressionAnnals of oncology, 2019-10, Vol.30 (10), p.1653-1659 [Peer Reviewed Journal]2019 THE AUTHORS ;The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz288 ;PMID: 31435660Full text available |
|
14 |
Material Type: Article
|
miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancerPloS one, 2017-02, Vol.12 (2), p.e0171751-e0171751 [Peer Reviewed Journal]COPYRIGHT 2017 Public Library of Science ;COPYRIGHT 2017 Public Library of Science ;2017 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2017 Chen et al 2017 Chen et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0171751 ;PMID: 28199399Full text available |
|
15 |
Material Type: Article
|
Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics studyPLoS medicine, 2018-11, Vol.15 (11), p.e1002711 [Peer Reviewed Journal]COPYRIGHT 2018 Public Library of Science ;COPYRIGHT 2018 Public Library of Science ;2018 Hosny et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Hosny et al 2018 Hosny et al ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1002711 ;PMID: 30500819Full text available |
|
16 |
Material Type: Article
|
Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancerBMC immunology, 2018-01, Vol.19 (1), p.3-3, Article 3 [Peer Reviewed Journal]COPYRIGHT 2018 BioMed Central Ltd. ;COPYRIGHT 2018 BioMed Central Ltd. ;2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2018 ;ISSN: 1471-2172 ;EISSN: 1471-2172 ;DOI: 10.1186/s12865-018-0241-4 ;PMID: 29361917Full text available |
|
17 |
Material Type: Article
|
Neutrophilia as prognostic biomarker in locally advanced stage III lung cancerPloS one, 2018-10, Vol.13 (10), p.e0204490-e0204490 [Peer Reviewed Journal]COPYRIGHT 2018 Public Library of Science ;COPYRIGHT 2018 Public Library of Science ;2018 Schernberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;2018 Schernberg et al 2018 Schernberg et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0204490 ;PMID: 30304046Full text available |
|
18 |
Material Type: Article
|
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer PatientsClinical cancer research, 2018-07, Vol.24 (13), p.3097-3107 [Peer Reviewed Journal]2018 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Jul 1, 2018 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-17-2310 ;PMID: 29506987Full text available |
|
19 |
Material Type: Article
|
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancerBMC cancer, 2024-05, Vol.24 (1), p.569-569 [Peer Reviewed Journal]2024. The Author(s). ;COPYRIGHT 2024 BioMed Central Ltd. ;2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2024 ;ISSN: 1471-2407 ;EISSN: 1471-2407 ;DOI: 10.1186/s12885-024-12315-5 ;PMID: 38714983Full text available |
|
20 |
Material Type: Article
|
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCThe New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1809697 ;PMID: 30280658Full text available |